摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-哌啶基)-1,2-苯并异恶唑盐酸盐 | 84163-22-4

中文名称
3-(4-哌啶基)-1,2-苯并异恶唑盐酸盐
中文别名
3-(哌啶-4-基)苯并[D]异恶唑;3-(哌啶-4-基)苯并[D]异恶唑
英文名称
3-(piperidin-4-yl)benzo[d]isoxazole hydrochloride
英文别名
3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride;3-piperidin-4-yl-1,2-benzoxazole;hydrochloride
3-(4-哌啶基)-1,2-苯并异恶唑盐酸盐化学式
CAS
84163-22-4
化学式
C12H14N2O*ClH
mdl
——
分子量
238.717
InChiKey
JVRIOVDBNNWSHA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    313-315 °C (decomp)
  • 溶解度:
    DMSO(少许)、甲醇(少许)、水(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    2.72
  • 重原子数:
    16
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    38.1
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    2-8°C,惰性气氛

SDS

SDS:f881cf9827cec132616a32ef33cfee2c
查看

反应信息

  • 作为反应物:
    描述:
    3-(4-哌啶基)-1,2-苯并异恶唑盐酸盐 在 sodium hydride 、 potassium hydroxide 作用下, 以 四氢呋喃N,N-二甲基甲酰胺 为溶剂, 反应 28.0h, 生成 6-{2-[4-(1,2-benzoisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one
    参考文献:
    名称:
    CONDENSED LACTAM DERIVATIVE
    摘要:
    本发明涉及一种用于治疗神经精神疾病的药物,包括以下化合物(1)的药物学上可接受的盐,作为活性成分。
    公开号:
    US20200172543A1
  • 作为产物:
    描述:
    盐酸盐酸羟胺 、 sodium hydride 、 sodium hydroxide 作用下, 以 四氢呋喃乙醇N,N-二甲基甲酰胺 为溶剂, 反应 103.0h, 生成 3-(4-哌啶基)-1,2-苯并异恶唑盐酸盐
    参考文献:
    名称:
    Revised Pharmacophore Model for 5-HT2A Receptor Antagonists Derived from the Atypical Antipsychotic Agent Risperidone
    摘要:
    Pharmacophore models for 5-HT2A receptor antagonists consist of two aromatic/hydrophobic regions at a given distance from a basic amine. We have previously shown that both aromatic/hydrophobic moieties are unnecessary for binding or antagonist action. Here, we deconstructed the 5-HT2A receptor antagonist/serotonin-dopamine antipsychotic agent risperidone into smaller structural segments that were tested for 5-HT2A receptor affinity and function. We show, again, that the entire risperidone structure is unnecessary for retention of affinity or antagonist action. Replacement of the 6-fluoro-3-(4-piperidinyl)-1,2-benz[d]-isoxazole moiety by isosteric tryptamines resulted in retention of affinity and antagonist action. Additionally, 3-(4-piperidinyl)-1,2-benz[d]isoxazole (10), which represents less than half the structural features of risperidone, retains both affinity and antagonist actions. 5-HT2A receptor homology modeling/docking studies suggest that 10 binds in a manner similar to risperidone and that there is a large cavity to accept various N-4-substituted. analogues of 10 such as risperidone and related agents. Alterations of this "extended" moiety improve receptor binding and functional potency. We propose a new risperidone-based pharmacophore for 5-HT2A receptor antagonist action.
    DOI:
    10.1021/acschemneuro.8b00637
点击查看最新优质反应信息

文献信息

  • [EN] 1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA<br/>[FR] 1,2,4-TRIAZOLES COMME MODULATEURS ALLOSTÉRIQUES DE L'ACTIVITÉ DES RÉCEPTEURS MGLU5 POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE OU DE LA DÉMENCE
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2013083741A1
    公开(公告)日:2013-06-13
    This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
    这项发明涉及公式(I)化合物的用途,它们作为mGlu5受体活性的正变构调节剂,包含这些化合物的药物组合物,以及使用它们作为治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的方法,如精神分裂症或认知衰退,例如痴呆或认知障碍。A、B、X、R1、R2、R3的含义在描述中给出。
  • NOVEL COMPOUNDS
    申请人:GRAUERT Matthias
    公开号:US20130150341A1
    公开(公告)日:2013-06-13
    This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R 1 , R 2 , R 3 have meanings given in the description.
    本发明涉及式I化合物、它们作为mGlu5受体活性的正变构调节剂的应用、含有该化合物的药物组合物,以及使用它们作为治疗和/或预防与谷氨酸功能障碍相关的神经和精神障碍的剂,如精神分裂症或认知下降,如痴呆或认知障碍。A、B、X、R1、R2、R3的含义如说明书中所述。
  • 1-(arylthioalkyl, arylaminoalkyl or arylmethylenealkyl)-4-(heteroaryl)
    申请人:Hoechst Roussel Pharmaceuticals, Inc.
    公开号:US05605913A1
    公开(公告)日:1997-02-25
    Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. the compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    杂芳基哌啶、吡咯烷和哌嗪作为抗精神病和镇痛剂是有用的。这些化合物特别适用于通过向哺乳动物施用治疗精神病有效量的其中一种化合物来治疗精神病。这些化合物的长效衍生物对于提供这些化合物的长期作用是有用的。通过向哺乳动物施用镇痛有效量的其中一种化合物,这些化合物也作为镇痛剂有用。
  • Heteroarylpiperidines, pyrrolidines and piperazines and their use as
    申请人:Hoechst-Roussel Pharmaceuticals, Inc.
    公开号:US05364866A1
    公开(公告)日:1994-11-15
    Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    吡啶基哌啶、吡咯烷和哌嗪等杂环哌啶类化合物可用作抗精神病和镇痛剂。这些化合物特别适用于通过向哺乳动物施用其中一种化合物的抗精神病有效量来治疗精神病。这些化合物也可通过向哺乳动物施用其中一种化合物的镇痛有效量来用作镇痛剂。
  • 3-(heteroaryl)-1-\x9b(2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and
    申请人:Hoechst Marion Roussel, Inc.
    公开号:US05776963A1
    公开(公告)日:1998-07-07
    Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. Depot derivatives of the compounds are useful for providing long acting effects of the compounds. The compounds are also useful as analgesics by administering a pain-relieving effective amount of one of the compounds to a mammal.
    吡啶基哌啶、吡咯烷和哌嗪等杂环哌啶类化合物在抗精神病和镇痛药物中具有用途。这些化合物特别适用于通过向哺乳动物施用其中一种化合物的精神病治疗有效量来治疗精神病。这些化合物的缓释衍生物对提供化合物的长效作用也是有用的。这些化合物还可通过向哺乳动物施用其中一种化合物的止痛有效量来用作镇痛剂。
查看更多

同类化合物

苯并异恶唑Hsp90抑制剂 苯并[d]异噁唑-7-醇 苯并[d]异噁唑-5-胺 苯并[d]异噁唑-5-磺酰氯 苯并[D]异恶唑-3-甲酸 苯[D]异恶唑-3-醇 羟基伊洛哌酮 甲基6-氨基-1,2-苯并恶唑-3-羧酸酯 环己酮,2,3-二甲基-6-(1-甲基乙基)-,[2R-(2α,3ba,6ba)]-(9CI) 帕潘立酮杂质1 奈氟齐特 四氢-4-[[[4-[[[4-[[(3R)-四氢-3-呋喃基]氧基]-1,2-苯并恶唑-3-基]氧基]甲基]-1-哌啶基]甲基]-2H-吡喃-4-醇 唑尼酰胺-d4 唑尼沙胺钠 唑尼沙胺13C2-15N 唑尼沙胺 呋喃并[3,4:3,4]环丁二烯并[1,2:3,4]环丁二烯并[1,2-d]异噻唑(9CI) 呋喃并[3,4-f][1,2]苯并恶唑 呋喃并[3,4-e][1,2]苯并恶唑 呋喃并[3,2-g][1,2]苯并恶唑 呋喃并[3,2-f]-1,2-苯并异恶唑 呋喃并[2,3-f][1,2]苯并恶唑 呋喃并[2,3-e][1,2]苯并恶唑 叔-丁基(6-溴苯并[D]异噻唑-3-基)氨基甲酯 化合物 T29498 佐尼氯唑 伊潘立酮(R)-羟基杂质 alpha-甲基-3-苯基-1,2-苯并异恶唑-7-乙酸 [1,2]恶唑并[5,4-f][1,2]苯并恶唑 [1,2]恶唑并[5,4-e][2,1,3]苯并恶二唑 [1,1'-联苯基]-3-醇,2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)- [(3-氨基-1,2-苯并异恶唑-5-基)甲基]氨基甲酸叔丁酯 N,N-二甲基唑尼沙胺杂质 N-甲氧基-N-甲基苯并[d]异恶唑-3-甲酰胺 N-甲基唑尼沙胺 N-乙基苯异恶唑酮四氟硼酸盐 N-[(1,2-苯并恶唑-3-基甲基)磺酰基]乙酰胺 N-(苯并[D]异恶唑-3-基氧基-二甲基氨基-磷酰)-N-甲基-甲胺 N-(6-己酸)唑尼沙胺 7-硝基-1,2-苯并恶唑 7-甲氧基-3-甲基-1,2-苯并恶唑 7-甲基苯并[d]异恶唑-3-醇 7-溴苯并[d]异噁唑 7-溴苯并[D]异恶唑-3(2H)-酮 7-溴-3-氯苯并[D]异恶唑 7-溴-1,2-苯并恶唑-3-胺 7-氯-苯并[d]异恶唑 7-氟苯并[d]异噁唑-3-胺 7-氟-苯并[d]异噁唑-3-醇 6-苯基苯并[d]异噁唑-3-胺